Dova Pharmaceuticals
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$2.7Mgeneral payments (2019-2025)
$2,656research payments (2019-2025)
4,152clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Nashat Gabrail | Canton, OH | $173,117.55 | |
| Steven Fein | Miami, FL | Hematology & Oncology | $106,726.72 |
| Moshe Levy | Dallas, TX | Medical Oncology | $105,543.14 |
| Hillary Maitland | Charlottesville, VA | Hematology (Internal Medicine) | $104,361.34 |
| Siamak Saadat | Colton, CA | Hematology & Oncology | $83,946.39 |
| Srikanth Nagalla | Miami, FL | Hematology & Oncology | $62,513.64 |
| Wajahat Khan | Grosse Pointe Woods, MI | Medical Oncology | $55,220.93 |
| Sammy Saab | Los Angeles, CA | Gastroenterology (Internal Medicine) | $54,527.85 |
| Ralph Boccia | Bethesda, MD | Hematology & Oncology | $54,384.27 |
| Tarek Chidiac | Columbus, OH | Hematology & Oncology | $53,891.76 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.